Price disclosure through TV advertising may reduce consumer interest in high-priced drugs

Requiring pharmaceutical companies to disclose prices in direct-to-consumer pharmaceutical advertising could potentially reduce interest in high-priced drugs, according to findings presented in JAMA Internal Medicine.
“In the ‘American Patients First’ blueprint released in May 2018, the Trump administration proposed including the drug price in any direct-to-consumer pharmaceutical advertising as an approach to lower prescription drug prices,” Jace B. Garrett, PhD, CMA, of the School of Accountancy, College of Business, at Clemson University in South Carolina, and

Full Story →